Clinical Trials Logo

Gastritis clinical trials

View clinical trials related to Gastritis.

Filter by:

NCT ID: NCT01240096 Recruiting - Clinical trials for Functional Dyspepsia

Mirtazapine Versus Placebo in Functional Dyspepsia

Start date: September 2006
Phase: Phase 4
Study type: Interventional

Double-blind randomized controlled trials of 8 weeks mirtazapine 15 mg daily or placebo, followed by 8 weeks of open-label mirtazapine 15 mg daily

NCT ID: NCT01232114 Recruiting - Clinical trials for Functional Dyspepsia(FD) Was Studied

Safety Study of a Chinese Herbal Formula Simotang Oral Liquid for the Treatment of Functional Dyspepsia

SMT
Start date: October 2010
Phase: N/A
Study type: Observational

Functional dyspepsia (FD) is a common functional gastrointestinal disorder and is steadily becoming a public health problem.Simotang is a classical formula that has been used to treat gastrointestinal disorders for hundreds of years [9] and was approved as an oral liquid drug by the Chinese National Food and Drug Administration in the 1980s.In this study,patients with functional dyspepsia were divided according to the inclusive criteria into treatment group and control group randomly, who were given Simo decoction or Domperidone tablets for 14 days。And then the gastric emptying, Symptoms in plasma were observed before and after treatment in mult-center.

NCT ID: NCT01226134 Recruiting - Clinical trials for Functional Dyspepsia

Effect Of Itopride On Gastric Emptying And Accommodation In Patients With Functional Dyspepsia

EIGEAPFD
Start date: February 2009
Phase: N/A
Study type: Interventional

Pathogenesis of functional dyspepsia is poorly understood. Gastrointestinal motor abnormalities, Helicobacter pylori infection, impaired gastric accommodation to a meal, hypersensitivity of the afferent nerves of the gut, psychological disturbances and central nervous system dysfunction have been proposed. Pharmacological treatments for patients with functional dyspepsia remain unsatisfactory. Only small benefits relative to placebo have been found with histamine H2 receptor antagonists, proton pump inhibitor and Helicobacter pylori eradication. Itopride is a dopamine antagonist with acetylcholinesterase inhibitory actions. This agent is currently indicated for patients with various upper GI symptoms. This study is aimed to evaluate the effect of Itopride on gastric emptying(by 13-C Octanoic acid breath Test), accommodation (by Gastric Scintigraphy SPECT and slow nutrient drinking test)and symptoms in FD patients

NCT ID: NCT01212016 Terminated - Clinical trials for Eosinophilic Esophagitis

Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders

Start date: August 30, 2010
Phase: N/A
Study type: Observational

Background: - Food allergies are characterized by abnormal immune system responses to certain foods, such as peanuts, strawberries, and shellfish. Some individuals with these allergies have immediate allergic reactions on contact with the food in question and need immediate treatment to prevent severe complications. In contrast, eosinophil-associated gastrointestinal disorders are related disorders in which white blood cells in the intestinal tract react to certain foods, causing abdominal pain, nausea, and other digestion problems. Researchers are interested in studying these conditions to better understand how the immune system responds to food allergies. Objectives: - To examine how the immune system responds to food allergens. - To examine how certain white blood cells contribute to disease in individuals with food allergies and other inflammatory diseases. Eligibility: - Individuals between 18 and 65 years of age who have a history of (a) severe allergic reaction to peanuts (and have peanut-specific antibodies), (b) allergy or inflammatory disease, or (c) eosinophil-associated gastrointestinal disorder (with at least two documented food allergies). - Healthy volunteers between 18 and 65 years of age who have no known allergies or asthma. Design: - All participants will have a screening visit and a procedure visit. The procedure visit will take place within 30 to 60 days of the screening visit, and will take 3 to 4 hours depending on the procedure(s) done. - Participants will be screened with a physical examination and medical history, and will provide blood samples for testing. Participants with peanut or other allergies will have additional tests to determine their levels of sensitivity to certain foods. Participants with eosinophil-associated gastrointestinal disorder will provide stool samples for testing. - At the procedure visit, participants with peanut allergies and participants with other allergies will provide blood samples and have leukapherisis to collect white blood cells for examination. - At the procedure visit, healthy volunteers and participants with eosinophil-associated gastrointestinal disorder will provide blood samples and have leukapherisis to collect white blood cells for examination. In addition, some but not all of these participants will have a procedure called esophagogastroduodenoscopy (EGD), which will examine the esophagus, stomach, and small intestine. Participants who are scheduled to have EGD will be asked to fast for 6 hours before the procedure.

NCT ID: NCT01190657 Completed - Gastric Ulcer Clinical Trials

Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer

Start date: May 2010
Phase: Phase 4
Study type: Interventional

This is a self-controlled, open, multiple-center clinical trial.

NCT ID: NCT01119768 Completed - Chronic Gastritis Clinical Trials

Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients

Start date: April 2010
Phase: Phase 4
Study type: Interventional

To compare the symptom control rate between 8 weeks esomeprazole treatment regimen group and 2 weeks esomeprazole treatment regimen group in co-diagnosed NERD and chronic gastritis patients, as evaluated by GerdQ after 24 weeks maintenance treatment/follow up.

NCT ID: NCT01089543 Completed - Clinical trials for Functional Dyspepsia

A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of rabeprazole compared to placebo in Japanese subjects with Functional Dyspepsia.

NCT ID: NCT01053871 Completed - Clinical trials for Functional Dyspepsia

Propofol Versus Midazolam With Fentanyl for EGD Endomicroscopy

Start date: January 2010
Phase: N/A
Study type: Interventional

This trial aims to compare the endomicroscopic image quality and sedation efficacy of propofol or midazolam with fentanyl.

NCT ID: NCT01040455 Terminated - Clinical trials for Functional Dyspepsia

Lansoprazole for Subgroups of Functional Dyspepsia

Start date: December 2009
Phase: Phase 4
Study type: Interventional

Pharmacotherapy for functional dyspepsia remains unsatisfactory. Previous randomized trials reported conflicting results on clinical effectiveness of proton pump inhibitor in patients with functional dyspepsia. This study aims to examine whether lansoprazole 15mg is more effective than placebo for functional dyspepsia in Taiwanese patients, and to investigate the association between subgroups of patients and therapeutic response.

NCT ID: NCT01021475 Recruiting - Clinical trials for Functional Dyspepsia

Does Visceral Manipulation Works in Treating Functional Dyspepsia?

Start date: November 2009
Phase: Phase 1
Study type: Interventional

The goal of this study is to determine if Visceral Manipulation (VM) is effective in treating Functional Dyspepsia in addition to drug therapy. Null hypothesis is that VM does not influence FD symptoms.